Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS)
Solicitation from the National Institutes of Health. Due Nov 30, 2026, 5:00 PM (UTC-5), 43 days left.
| Solicitation number | ARPA-H-SOL-26-164 |
|---|---|
| Agency | National Institutes of Health |
| Office | Advanced Research Projects Agency for Health (ARPA-H) |
| Notice type | Solicitation |
| Set-aside | None |
| Trade (NAICS) | Research and Development in Biotechnology (except Nanobiotechnology) (541714) |
| Product or service code | AN13 |
| Posted | Sep 30, 2026 |
| Response deadline | Nov 30, 2026, 5:00 PM (UTC-5) (43 days left) |
Official notice and attachments
Description
The Advanced Research Projects Agency for Health (ARPA-H) posts this solicitation in support of its Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) Program. ARPA-H anticipates multiple Other Transaction Agreement awards will result from this opportunity. Interested parties are invited to review the attached Solicitation (ARPA-H-SOL-26-164) and associated attachments.
As detailed in Special Notice ARPA-H-SN-26-164, ARPA-H will host an informational webinar on 15 OCT 2026 and a 2-day Proposers’ Day on 6 and 9 NOV 2026 in support of SURPASS. All questions related to SURPASS should be submitted to [email protected].
About the buyer
The National Institutes of Health awarded $5.8 billion in contracts in the last 12 months; its biggest suppliers were Leidos Biomedical Research Inc, M. A. Mortenson Company and Deloitte Consulting LLP. See what NIH is buying now.